Short answer
Voyager Therapeutics, Inc. (VYGR) filed an 8-K current report with the SEC on October 21, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Robin Swartz appointed President effective October 20, 2026, strengthening internal succession continuity.
Voyager Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Robin Swartz appointed President effective October 20, 2026, strengthening internal succession continuity
- Expected CEO transition after first-quarter 2027 VY1706 acute safety data, with Alfred Sandrock remaining on the Board
- Annual salary $625,000, target cash bonus 50% of base salary
- Equity award: option for 318,500 shares plus restricted stock units for 68,250 shares
- Change-in-control severance includes 12 months’ salary, pro rata bonus, COBRA coverage and full equity acceleration
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Voyager Therapeutics, Inc. 8-K filings
Get the next VYGR 8-K as it lands
Follow VYGR for push alerts, or ask the research agent what this filing means.